Full Breakdown
Chinese Pharma Contractors Remain Bullish as U.S. Supply-Chain Push Meets Industry Resistance
8/17/2026, 9:44:47 PM
Market Resilience Amid Policy Pressure
China’s contract-research firms are maintaining strong market performance despite Washington’s recent initiatives to reduce reliance on Chinese pharmaceutical supply chains. Analysts attribute the upward share movement of Hong Kong-listed companies such as WuXi AppTec and Genscript Biotech to investors’ confidence that industry players are reluctant to abandon the cost advantages offered by Chinese manufacturing.
Recent Financial Results
Genscript Biotech reported an adjusted net profit of US$62.52 million for the six months ended June 30, reflecting a 203 percent year-on-year increase, according to a filing with the Hong Kong Stock Exchange. The company’s shares rose 4.8 percent to HK$26.08. WuXi AppTec’s stock gained 3 percent, reaching a new high of HK$203.40.
Growth Drivers: AI-Driven Drug Discovery
Chief Financial Officer Phil Zhou indicated that demand for integrated gene-to-protein solutions—particularly those linked to artificial-intelligence-driven drug discovery—has accelerated. He projected that AI-driven drug-discovery orders will double in the second half of the year and remain robust for several years. The life-science service segment, which includes DNA, RNA, peptide synthesis, and protein production, now carries the bulk of Genscript’s revenue.
Outlook and Guidance
Genscript raised its full-year guidance for the life-science service segment to a growth range of 25 to 30 percent. The company expects the AI-related demand surge to sustain its revenue expansion throughout the year. No official statements from U.S. agencies were provided in the source material, and the article reflects the available financial data and analyst commentary.
